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Abstract
Twenty-one liver transplants have been performed in Hawaii in
the initial five years. Hepatitis C was the most common reason for
liver transplant. Twenty patients are currently alive, and 93.3% of
patients survived one year. Of those one year post transplant, 60%
have returned to work. Liver transplant can be performed in Hawaii
with results comparable to mainland centers.
Methods and Materials
This is a retrospective review of patients who underwent liver
transplant at St. Francis Medical Center from May 1993 to May
1998. Records were reviewed for demographic data, etiology of
liver disease, status at the time of transplant, length of surgery,
amount of blood transfused, length of intensive care unit (ICU) and
hospital stay, complications and outcome. We also determined cold
ischemic time (CIT), which is the length of time between aortic
cross-clamp in the cadavenc donor and the time ofrevascularization
of the liver in the recipient. Outcome was determined by patient and
allograft survival, number of rejection episodes, recurrence of
disease, need for retransplantation, and return to work.
We reviewed data on patients referred to our transplant center for
liver transplant evaluation during this same time period. Reasons for
not transplanting these patients at our center were noted.
We also reviewed demographic data on cadaveric donors for these
transplant recipients. Aggregate data on donors during this 5-year
period were also obtained from the Organ Donor Center of Hawaii,
the official Organ Procurement Organization (OPO) for the state of
Hawaii.
Results
Twenty-one liver transplants were performed at St. Francis Medi
cal Center in the first five years since inception of the program in
May 1993. There were 11 males and 10 females with a mean age of
52.0 years (range 39-62 years). In terms of race distribution, there
were 7 Caucasians, 6 Japanese, 5 Filipinos, and one tach for
Chinese, Korean, and Hispanic-American extraction. Etiology of
end-stage liver disease was predominantly Hepatitis C (13 of 21
patients). Other etiologies included alcoholic cirrhosis (3 patients),
Hepatitis B (2 patients), autoimmune hepatitis (2 patients) and
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cryptogenic (1 patient). Two patients also had hepatocellular cancer
at the time of transplant, in addition to their underlying disease.
(Hepatitis B in one and Hepatitis C in the other).
Seventeen patients were waiting at home when called in for liver
transplant. Four patients were in the hospital —2 in the intensive care
unit, and 2 on the general medical floor when a donor organ became
available.
Mean operative time was 9.1 ± 2.3 hours (range 6-15.5 hours).
Patients received a mean of 13.3 ± 18.0 units of packed red blood
cells (PRBCs). The amount of blood transfused in the last 16
transplants was 6.2 ± 3.3 units. This may be multifactorial and may
include the use of antifibrinolytic agents such as aprotonin given
intravenously during these most recent 16 procedures. Mean ICU
stay was 7.4 ± 11.4 days (range 1-49 days) with 11 patients
remaining in the ICU for 3 days or less. Mean hospital stay was 18.0
± 16.7 days (range 6-71 days) with 10 patients hospitalized for less
than 10 days. (HospitalfICU length of stay based on 20 patients, as
one patient currently hospitalized)
Early complications which required return to the operating room
within the first 30 days, included bleeding (2 patients) and bile leak
requiring biliary reconstruction (2 patients). One patient also re
quired return to the operating room after she accidentally removed
her T-tube on post-operative day 4, and another patient required
drainage of a mucocele of the cystic duct stump.
Infectious complications in the initial hospitalization included
Vancomycin-resistant enterococcal peritonitis in one patient and
fungal line sepsis in a second patient. Two patient developed
opportunistic infections during the post-transplant period. One of
these patients developed a Herpes simplex viral infection mani
fested by skin lesions, fever, and mouthlpharynx ulcerations. This
resolved with use of acyclovir and lowering of immunosuppression.
A second patient developed a respiratory symptoms and a lung mass
with needle biopsy yielding Candida albicans. This mass resolved
with a course of fluconazole.
Two patients suffered cerebrovascular accidents 1.5 and 28 months
post-transplant. One of these patients also sustained a femoral neck
fracture shortly after the cerebrovascular accident. Both patients
have recovered well with no noticeable residual deficits.
Thirteen patients underwent transplant for Hepatitis C. Of these,
seven have had liver biopsies for elevated liver enzymes. Five of
these demonstrated histologic evidence of recurrence. Immunosup
pression has been lowered in these patients. One patient has been
placed on interferon for histologic progression of hepatitis C, with
evidence of early fibrosis. There has been no graft loss due to
recurrent hepatitis C. Two patients with hepatitis B, have been
followed closely for recurrence of disease. Hepatitis B immune
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globulin has been administered prophylactically every 3-4 weeks to
maintain a Hepatitis B surface antibody titer of greater than 300
mIU/ml. Patients have also been placed on lamivudine, a nucleoside
analog which decreases the replication of the hepatitis B virus.
Neither patient has demonstrated any evidence of recurrence of
disease.
During this same time period, a total of 53 other patients were
referred to our center for possible liver transplant evaluation. Six
patients were evaluated and placed on the waiting list, but expired
from complications of liver failure before a donor liver became
available. Two patients were removed from the waiting list —one
because the patient no longer desired transplant and the other due to
alcohol recidivism after 2 years of abstinence. Ten patients were
evaluated but decided to pursue transplant at mainland centers for
various reasons. Twenty-three patients were not completely evalu
ated for either medical reasons (other severe underlying diseases.
HIV positivity. or sepsis). psychosocial reasons (recent substance
abuse, severe psychiatric problems) or financial reasons (insurance
coverage contracted with mainland centers). Twelve patients did not
pursue transplant evaluation any further despite physician referral
and multiple attempts at contacting them.
Donor livers were obtained from the state of Hawaii only. No
imported livers from the mainland were accepted during this time
period. Mean donor age was 34.0 ±15.2 years (range 12 to 55 years.)
During this time period 41 livers were sent to mainland centers,
because of inappropriate size or blood type for the potential recipi
ents on our list. Several of these livers were of marginal quality (age
>55 years, elevated liver tests, andJor high doses of vasopressors in
the donor) and were not felt to be suitable at that time. Mean cold
ischemia time was 388 ± 110 minutes (range 168-6 19 minutes).
Six patients experienced transplant rejection. Five of these pa
tients improved with a high-dose intravenous steroid bolus (500-
1000mg). The sixth patient required a course of OKT3 (monoclonal
antibody). Of the 15 patients who are at least 1-year post transplant,
14 are alive and functioning well, for a one year survival of 93.3%
(See figure 1). One patient died at 3 months from complications of
portal vein thrombosis and sepsis. No patient has required
retranspiantation. Of these 15 patients, 9 (60%) are currently work
ing at part-time or full-time jobs.
Discussion
Five years ago our group published an article in this journal on
Hawaii’s first liver transplant. Since that time, the transplant pro
gram in Hawaii has continued to thrive and has demonstrated that
liver transplants can be performed here with results comparable to
other US transplant centers. Our 1 year patientlgraft survival was
93.3% and nationwide, the 1 year patient and graft survival was
87.0% and 79.1%, respectively. One year survival by UNOS
(United Network for Organ Sharing) status was 92.3%, 100%, and
50% for status 3, 2, and 1 respectively. This is compared to 84.0%,
77.1% and 67.1% for the national data.’ (Status 1 patients are
waiting in the ICU, see below)
Liver transplantation has become a standardized treatment for
end-stage liver disease. Surgeons have refined the operative proce
dure, and many new immunosuppressive drugs have helped mini
mize rejection. Other new advances include successful use of
Hepatitis B immune globulin and nucleoside analogs, such as
lamivudine to prevent recurrence of Hepatitis B.2 We have also
begun to understand the appropriate use of liver transplant for
malignancies. When done in patients with smaller size (<5 cm), and
without lymphatic spread, vascular invasion, or multiple nodules,
the prognosis is better. Adjuvant modalities such as
chemoembolization, and percutaneous ethanol may be used to treat
the tumor while waiting for the appropriate donor.3These modalities
may also prevent recurrence of cancer, but it is difficult to know —
they may only be delaying the recurrence. Longer follow-up studies
will be necessary.
We still need to find the appropriate treatment for recurrent
Hepatitis C. Whether interferon and use of new antiviral agents will
help has not been completely determined.2Ultimately finding ways
to treat Hepatitis C before progression to end-stage cirrhosis, will be
the most beneficial.
The major problem facing all liver transplant programs, however,
has been that of a limited supply of donor organs for the rapidly
growing waiting list. Because of this, the transplant community
continuously tries to improve the process of donor allocation and
distribution in order to maximize use of this precious resource.
The indications for liver transplant continue to include irrevers
ible advanced chronic liver disease, fulminant liver failure, meta
bolic liver diseases and certain neoplastic diseases. We continue to
look for complications such as intractable ascites, variceal bleeding,
encephalopathy, malnutrition, hepatorenal syndrome and recurrent
spontaneous bacterial peritonitis as indications that a liver transplant
will be needed soon. However, we are now unable to place a patient
on the waiting list until specific criteria are met
Listing criteria is based on the Childs-Turcotte-Pugh score (CTP
score, see table 1). Each patient is assigned a score based on albumin,
bilirubin, prothrombin time, encephalopathy, and ascites. The score
is used to give each patient a status.
Status 1: Fulminant liver failure
Status2A: CTP score l0 in ICU and have at least 1 of the
following:
acute variceal bleed, hepatorenal syndrome, refractory
acites, stage IlLIlVencephalopathy
Figure 1: Kaplan-Meier Survival Curve for liver transplant patients
1993-1998.
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Patient cannot be listed as Status 2A if extrahepatic
sepsis, high dose or 2 or more pressures, or irreversible
multi-organ failure
Status 2B: CTP score 10 or CTP score 7 and 1 of the following:
acute variceal bleed, hepatorenal syndrome, spontane
ous bacterial peritonitis, refractory ascites
Status 3: Patient requires continuous medical care, with CTP
score 7
Table 1: Summary of Data
Number of Patients 21
Mean age 52.0 years
M:F 11:10
Etiology
Hepatitis C 13 patients
Alcohol 3 patients
Hepatitis B 2 patients
Autoimmune 2 patients
Cryptogenic 2 patients
Mean operative time 9.1 ± 2.3 hours
Mean, blood transfusions 13.3 ± 18.0 units
Mean ICU stay 7.4 ± 11.4 days
Mean hospital stay 18.0 ± 16.7 days
#with rejection 6 patients
#currently employed 9 patients
1 year graft/patient survival 93.3%
Table 2: Childs-Turcotte-Pu Ih Score
Points 1 2 3
Encephalopathy None Grade 1-2 Grade 3-4
Ascites Absent Slight Moderate
(controlled with
diuretics)
Bilirubin (mg/dl) <2 2-3 >3
Albumin (gldl) >3.5 2.8-3.5 <2.8
Prothrombin <4 4-6 >6
time (sec
prolonged)
For primary <4 4-10 >10
biliary cirrhosis,
other cholestatic
liver diseases.
Bilirubin (mg/dl)
United Network for Organ Sharing (UNOS) is an organization,
which exchanges scientific information, compiles statistical data,
promotes organ donation and creates policy for all organ allocationl
distribution. Members of UNOS include transplant centers, organ
procurement organizations, transplant physicians, histocompatibil
ity laboratories, and members of the community including trans
plant recipients and donor families.
UNOS has developed various policies for organ allocation de
pending on the type of organ transplanted. UNOS has divided the US
into 11 different regions — Hawaii is a part of Region 5. Factors
which are generally involved in organ allocation include blood type,
size of the patient, waiting time, and medical urgency status.
When a donor liver becomes available, it is offered to the patient
of compatible blood type and size and in the order of medical
urgency (Status 1 first) locally, then within the region, then within
the United States (US). If a liver becomes available in Hawaii, it is
offered to local patients first. If no suitable patient is found then it
will be offered to the centers within Region 5. If no one in region S
accepts the organ, it may be used anywhere in the US.
UNOS has developed the standardized listing criteria outlined
above in order to avoid listing patients too early or transplanting
patients with unreasonable likelihood for survival. It allows for
some unifonnity in listing practices between the 121 liver transplant
centers in the US.
The most controversial issue currently facing the transplant com
munity is the intervention of the Department of Health and Human
Services (HHS) on the practices of UNOS. Several of their prin
ciples include; “Transplant patients are best served by an organ
allocation system that functions equitably on a nationwide basis”
and “Organs should be equitably allocated to all patients, giving
priority to those patients in most urgent medical need of transplan
tation, in accordance with sound medical judgment”, Also, “The
Secretary of HHS should represent the public interest by setting
broad goals for the OPTN (Organ Procurement and Transplantation
Network) and by overseeing OPTN policy development and opera
tions with a view toward ensuring that the goals are being addressed
in a reasonable manner”.5While transplanting the sickest patients
seems to make sense to the average person, studies have demon
strated that the sickest patients have the poorest survival and the
highest hospital charges.’45Furthermore, if there is a single national
list of patients, donor organs may end up traveling longer distances
to the sickest patients—thus prolonging the cold ischemic time and
threatening graft function.
How any new rules will affect Hawaii is not clear at this time. Qj
program has had difficulty transplanting the sickest patients —with
six patients dying while waiting on the list. Furthermore, only 9.5%
of all patients transplanted were waiting in the ICU(status 1 or 2A)
compared to the national average of 16%.’ This may be due in part.
to geographic isolation and difficulty sharing organs with mainland
centers. The basic problem underlying the entire controversy or
organ distribution, however, is the lack of enough donor organs to
meet the ever-burgeoning list of patients waiting for transplant.
Physicians and all health care professionals, should do their part for
the organ shortage by promoting organ donation and promptly
referring any potential donor.
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